This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Surgalign Holdings's Median PS Value or its related term are showing as below:
SRGAQ's Price-to-Median-PS-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.785 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Surgalign Holdings Median PS Value Historical Data
The historical data trend for Surgalign Holdings's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Surgalign Holdings's Median PS Value
For the Medical Devices subindustry, Surgalign Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgalign Holdings's Price-to-Median-PS-Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Surgalign Holdings's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Surgalign Holdings's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.0534.
Surgalign Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.234.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgalign Holdings (OTCPK:SRGAQ) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Surgalign Holdings's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.018
/
10.78
=
0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgalign Holdings Median PS Value Related Terms
Thank you for viewing the detailed overview of Surgalign Holdings's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Surgalign Holdings (Surgalign Holdings) Business Description
Surgalign Holdings Inc is a global medical technology company advancing the science of spine care, focused on delivering innovative solutions that drive superior clinical and economic outcomes. The company continues to invest in clinically validated innovation to deliver the Best surgical outcomes and improve patient's lives. It markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors. The U.S. market accounts for the vast majority of revenue. It has commercial and design centers in San Diego, California, and Wurmlingen, Germany.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRGAQ has been successfully added to your 